Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

Usmani, Saad Z. ^{[2
]}

Quach, Hang ^{[3
]}

Dimopoulos, Meletios-Athanasios ^{[4
]}

Fonseca, Rafael ^{[5
]}

McFadden, Ian ^{[6
]}

Yusuf, Akeem ^{[6
]}

Khurana, Monica ^{[6
]}

Obreja, Mihaela ^{[6
]}

Spencer, Andrew ^{[7
]}

机构：

[1] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[4] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens, Greece

[5] Mayo Clin, Scottsdale, AZ USA

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

[7] Monash Univ, Alfred Health, Clayton, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-204

引用

页码：S150 / S151

页数：2

共 50 条

[21] Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
Lee, Hans C.
Ramasamy, Karthik
Macro, Margaret
Davies, Faith E.
Abonour, Rafat
van Rhee, Frits
Hungria, Vania T. M.
Puig, Noemi
Ren, Kaili
Silar, Jiri
Enwemadu, Victoria
Cherepanov, Dasha
Leleu, Xavier
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 190 - 200
[22] Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation
Silbermann, Rebecca W.
Schmidt, Timothy Martin
Bal, Susan
Dhakal, Binod
Dholaria, Bhagirathbhai
Biltibo, Eden
Chhabra, Saurabh
Giri, Smith
Godby, Kelly N.
Gowda, Sonia
Medvedova, Eva
Cornell, Robert F.
Callander, Natalie S.
Costa, Luciano J.
EJHAEM, 2023, 4 (03): : 775 - 778
[23] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD ResponseAdapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial
Costa, Luciano J.
Chhabra, Saurabh
Callander, Natalie S.
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Silbermann, Rebecca W.
Godby, Kelly N.
Dhakai, Binod
Bai, Susan
Gin, Smith
Souza, Anitad
Schmidt, Timothy M.
Hall, Aric C.
Hardwick, Pamela
Cornell, Robert F.
Hari, Parameswaran
BLOOD, 2021, 138
[24] Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)
Norgaard, Jakob Nordberg
Abildgaard, Niels
Lysen, Anna
Tsykunova, Galina
Vangsted, Annette Juul
Joao, Cristina
Remen, Nora
Connelly, James P.
Revheim, Mona-Elisabeth R.
Schjesvold, Fredrik H.
BLOOD, 2021, 138
[25] A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide Lenalidomide, Dexamethasone (KC) Vs an Immunomodulatory Agent Containing Triplet (CTD/C') Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study
Jackson, Graham H.
Davies, Faith E.
Pawlyn, Charlotte
Cairns, David
Striha, Alina
Hockaday, Anna
Collett, Corinne
Jones, John R.
Kishore, Bhuvan
Garg, Mamta
Williams, Catherine
Karunanithi, Kamaraj
Lindsay, Jindriska
Jenner, Matthew
Cook, Gordon
Russell, Nigel H.
Kaiser, Martin
Drayson, Mark T.
Owen, Roger G.
Gregory, Walter M.
Morgan, Gareth
BLOOD, 2018, 132
[26] Lenalidomide Exposure Prior to Autologous Stem Cell Transplantation May Increase Risk of Venous Thromboembolism (VTE) in Patients with Multiple Myeloma (MM)
D'Angelo, Christopher Robert
Callander, Natalie S.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S143 - S144
[27] Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
Schmidt, Timothy Martin
Silbermann, Rebecca
Bal, Susan
Dhakal, Binod
Dholaria, Bhagirathbhai
Biltibo, Eden
Chhabra, Saurabh
Giri, Smith
Godby, Kelly N.
Gowda, Sonia
Medvedova, Eva
Callander, Natalie
Costa, Luciano J.
BLOOD, 2022, 140 : 10077 - 10078
[28] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)
Bringhen, Sara
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Mazza, Rita
Ronconi, Sonia
Corradini, Paolo
Lotti, Flavia
Cellini, Claudia
Falcone, Antonietta Pia
Galieni, Piero
Ria, Roberto
Belotti, Angelo
Mannina, Donato
Cafro, Anna Maria
Cangialosi, Clotilde
Vincelli, Iolanda Donatella
Lombardo, Alessandra
Larocca, Alessandra
Boccadoro, Mario
D'Agostino, Mattia
BLOOD, 2023, 142
[29] Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).
Ludwig, Heinz
Dimopoulos, Meletios A.
Masszi, Tamas
Spicka, Ivan
Rocafiguera, Albert Oriol
Hajek, Roman
Rosinol, Laura
Siegel, David Samuel DiCapua
Mihaylov, Georgi
Goranova-Marinova, Vesselina
Rajnics, Peter
Suvorov, Aleksandr
Niesvizky, Ruben
Jakubowiak, Andrzej J.
Miguel, Jesus San
Obreja, Mihaela
Aggarwal, Sanjay
Moreau, Philippe
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Impact of Autologous Hematopoetic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.
Bal, Susan
Godby, Kelly
Chhabra, Saurabh
Medvedova, Eva
Cornell, Robert F.
Hall, Aric C.
Silbermann, Rebecca W.
Innis-Shelton, Racquel
Dhakal, Binod
De Idiaquez, Diego
Hardwick, Pamela
Callander, Natalie S.
Hari, Parameswaran
Costa, Luciano J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S24 - S24

← 1 2 3 4 5 →